#-supreme-cart-case-studies-6-2801{picked-cards-data:[{"post_id":"arm-reasons-to-believe-in-cell-gene-therapy-analysis-august-2026"},{"post_id":"cell-gene-therapy-expansion-the-evolution-of-cgt-delivery-in-the-u-s"}];manual-cards-data:[{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/09\/cropped-Logo-1.png","image_alt":"","badge":"Case Study","heading":"An independent community practice delivered 41 outpatient CAR-T courses","text":"Virginia Oncology Associates treated 41 adults with outpatient CAR-T between April 2022 and December 2024,using its existing FACT-accredited transplant infrastructure,contracted apheresis and a regional hospital partner for ICU-level care.","url":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12950586\/","new_tab":"true"},{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/09\/cropped-Logo-1.png","image_alt":"","badge":"Case Study","heading":"A Montana health system built CAR-T readiness for a rural region","text":"Billings Clinic Cancer Center,already delivering autologous transplant,describes building readiness through multidisciplinary protocols,EHR safety alerts,staff education and defined communication with its emergency department and ICU. ","url":"\/wp-content\/uploads\/2026\/09\/practiceprofile-billing-clinic.pdf","new_tab":"true"}]}#-supreme-cart-key-arguments-5-2801{links-data:[{"text":"Visit FACT","url":"https:\/\/www.factweb.org\/forms\/store\/ProductFormPublic\/fact-standards-for-immune-effector-cells-in-the-community-clinical-setting-first-edition-digital-version","style":"solid","new_tab":"true"},{"text":"Visit AABB","url":"https:\/\/www.aabb.org\/blood-biotherapies\/biotherapies\/standards\/about-aabb-standards-and-accreditation-for-cellular-therapies","style":"solid","new_tab":"true"}]}#-supreme-cart-playbook-navigation-7-2801{topics-data:[{"title":"Operations & Infrastructure","description":"Staffing,space,and workflows that actually fit.","url":"\/playbook\/operations-and-infrastructure\/","cta_text":"Explore","accent":"blue"},{"title":"Contracting & Partnership","description":"Terms with manufacturers,payers,and partners.","url":"\/playbook\/contracting-and-partnerships\/","cta_text":"Explore","accent":"blue"},{"title":"Patient Selection & Support","description":"Identify,refer,and support eligible patients.","url":"\/playbook\/patient-selection-and-support\/","cta_text":"Explore","accent":"pink"}]}#-supreme-faq-accordion-4-2801{faqs-data:[{"question":"Standard operating procedures and training","answer":"Written SOPs keep care consistent as staff change and volume grows. Build or adapt procedures covering the quality management system,chain of identity and custody,labeling and label reconciliation,apheresis collection,cryostorage and thaw,bridging treatment,pre-medication and infusion,CRS and ICANS grading and management,emergency escalation and ICU transfer criteria,immunosuppressant access,patient and caregiver education,post-infusion observation and discharge,and outpatient monitoring."},{"question":"Chain of identity,chain of custody,and labeling","answer":"Products are patient-specific and cannot be replaced,so identity has to be verified at every handoff. Best practice records the manufacturer identifier and the Donation Identification Number at collection,then double-checks patient name,medical record number,date of birth,DIN and manufacturer identifier on the apheresis bag and again at product receipt,alongside packaging integrity,transit temperature,bag count and expiration date. Label reconciliation should be a written,two-person step."},{"question":"Data management and IT","answer":"Decide early where CAR-T information lives. Best practice places the apheresis order in the same computerized order entry system as the product prescription and administration record,which improves traceability and lets pharmacy confirm washout periods for G-CSF,cytotoxics and steroids. You also need a route for manufacturer portal documentation,certificates of analysis and delivery notes,and storage temperature monitoring with a 24-hour alarm."},{"question":"Physical infrastructure for infusion and monitoring","answer":"Identify dedicated space for infusion and for post-infusion monitoring. Think through how to collaborate to ensure adequate and timely adverse event management."},{"question":"Data collection and process improvement","answer":"Decide what you will measure before the first infusion. Useful measures include incidence and grade of CRS and ICANS,hospital admissions and ICU stays,and complete response at 100 days and one year. Submission to the CIBMTR registry is recommended but not required,while compliance with manufacturer or sponsor reporting is mandatory. Manufacturers remain required to follow patients for 15 years for long-term safety,due to FDA requirements."}]}